Exhibit 107
Calculation of Filing Fee Tables
Form S-3
(Form Type)
Kura Oncology, Inc.
(Exact Name of Registrant as Specified in its Charter)
Table 1: Newly Registered and Carry Forward Securities
| Security Type |
Security Class Title |
Fee Calculation or Carry Forward Rule |
Amount Registered | Proposed Maximum Offering Price Per Unit |
Maximum
Aggregate Price |
Fee Rate |
Amount of Registration Fee | |||||||||
|
Newly Registered Securities | ||||||||||||||||
| Fees to Be Paid |
Equity | Common Stock, par value $0.0001 per share | (1) | (2) | (2) | (2) | (1) | (1) | ||||||||
| Equity | Preferred Stock, par value $0.0001 per share | (1) | (2) | (2) | (2) | (1) | (1) | |||||||||
| Debt | Debt Securities | (1) | (2) | (2) | (2) | (1) | (1) | |||||||||
| Other | Warrants | (1) | (2) | (2) | (2) | (1) | (1) | |||||||||
| Equity | Common Stock, par value $0.0001 per share | Rules 457(o) and 457(r) | $150,000,000 | N/A | N/A | $0.00014760 | $22,140 | |||||||||
| Total Offering Amount | $150,000,000 (3) | $0.00014760 | $22,140 | |||||||||||||
| Total Fees Previously Paid | — | |||||||||||||||
| Total Fee Offsets | $22,140 (4) | |||||||||||||||
| Net Fee Due | $0 (4) | |||||||||||||||
| (1) | Pursuant to Rules 456(b) and 457(r), the registrant is deferring payment of all applicable registration fees. |
| (2) | Omitted pursuant to General Instructions II.E of Form S-3. An indeterminate number or amount, as the case may be, of common stock, preferred stock, debt securities and warrants are being registered hereunder as may from time to time be issued at indeterminate prices. The securities being registered hereunder may be convertible into or exchangeable or exercisable for other securities of any identified class, and may be sold separately or in combination with the other securities registered hereunder. In addition to the securities that may be issued directly under this registration statement, there is being registered hereunder such indeterminate aggregate number or amount, as the case may be, of the securities of each identified class as may from time to time be issued upon the conversion, exchange, settlement or exercise of other securities offered hereby. Separate consideration may or may not be received for securities that are issuable upon the conversion or exercise of, or in exchange for, other securities offered hereby. In addition, pursuant to Rule 416 under the Securities Act, the shares being registered hereunder include such indeterminate number of shares of common stock and preferred stock as may be issuable with respect to the shares being registered hereunder as a result of stock splits, stock dividends or similar transactions. |
| (3) | The securities registered hereunder may be sold separately or in a combination with other securities registered hereby. Does not include registration fees deferred in accordance with Rules 456(b) and 457(r) under the Securities Act, as described in Note (1) above. |
| (4) | On August 1, 2019, the registrant filed a registration statement on Form S-3, amended on August 21, 2019 and declared effective on August 28, 2019 (File No. 333-232947) (the “2019 Registration Statement”), registering the issuance of up to $200,000,000 of common stock, preferred stock, debt securities and warrants (the “2019 Securities”). The registration fee associated with the 2019 Securities was $24,240. Pursuant to the 2019 Registration Statement, the registrant sold $143,893,750 of 2019 Securities, which equates to an associated registration fee of $17,439.92 based on the total registration fee paid in connection with the filing of the 2019 Registration Statement. Accordingly, the unused registration fee paid in connection with the 2019 Registration Statement and the 2019 Securities is $6,800.08. |
On August 6, 2020, the registrant filed a registration statement on Form S-3, declared effective on August 18, 2020 (File No. 333-241663) (the “2020 Registration Statement”), registering the issuance of up to $300,000,000 of common stock, preferred stock, debt securities and warrants (the “2020 Securities”). The registration fee associated with the 2020 Securities was $38,940. The registrant has not sold any 2020 Securities pursuant to the 2020 Registration Statement. Accordingly, the unused registration fee paid in connection with the 2020 Registration Statement and the 2020 Securities is $38,940.
Pursuant to Rule 457(p) under the Securities Act, the registration fee applicable to the $150,000,000 of common stock of the registrant being registered hereby in the amount of $22,140 is offset by (i) $6,800.08 in registration fees previously paid by the registrant with respect to 2019 Securities that were registered but not issued pursuant to the 2019 Registration Statement and (ii) $15,339.92 in registration fees previously paid by the registrant with respect to 2020 Securities that were registered but not issued pursuant to the 2020 Registration Statement. Accordingly, no registration fees are being paid at this time. Concurrently with the filing of this registration statement, any offering of unsold 2019 Securities or 2020 Securities pursuant to the 2019 Registration Statement or 2020 Registration Statement, respectively, is hereby terminated.
Table 2: Fee Offset Claims and Sources
| Registrant or Filer Name |
Form Type |
File Number |
Initial Filing Date |
Filing Date |
Fee Offset Claimed |
Security Type Associated with Fee Offset Claimed |
Security Title Associated with Fee Offset Claimed |
Unsold Securities Associated with Fee Offset Claimed |
Unsold Aggregate Offering Amount Associated with Fee Offset Claimed |
Fee Paid with Fee Offset Source | ||||||||||||
| Rule 457(p) | ||||||||||||||||||||||
| Fee Offset Claims |
Kura Oncology, Inc. | S-3 | 333-232947 | 8/1/2019 | $6,800.08 (1) | Equity | Common Stock | N/A | $56,106,250 (1) | |||||||||||||
| Fee Offset Sources |
Kura Oncology, Inc. | S-3 | 333-232947 | 8/1/2019 | $6,800.08 (1) | |||||||||||||||||
| Fee Offset Claims |
Kura Oncology, Inc. | S-3 | 333-241663 |
8/6/2020 | $15,339.92 (1) | Equity | Common Stock | N/A | $300,000,000 (1) | |||||||||||||
|
Fee Offset Sources |
Kura Oncology, Inc. | S-3 |
333-241663 |
8/6/2020 | $15,339.92 (1) | |||||||||||||||||
| (1) | See Note (4) under Table 1 above. |